136 related articles for article (PubMed ID: 9698109)
1. Peptide specificity of high-titer anti-glutamic acid decarboxylase (GAD)65 autoantibodies.
Rharbaoui F; Granier C; Kellou M; Mani JC; van Endert P; Madec AM; Boitard C; Pau B; Bouanani M
Immunol Lett; 1998 Jul; 62(3):123-30. PubMed ID: 9698109
[TBL] [Abstract][Full Text] [Related]
2. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes.
Daw K; Powers AC
Diabetes; 1995 Feb; 44(2):216-20. PubMed ID: 7532143
[TBL] [Abstract][Full Text] [Related]
3. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.
Tremble J; Morgenthaler NG; Vlug A; Powers AC; Christie MR; Scherbaum WA; Banga JP
J Clin Endocrinol Metab; 1997 Aug; 82(8):2664-70. PubMed ID: 9253351
[TBL] [Abstract][Full Text] [Related]
4. Antibody cross-reactivity induced by the homologous regions in glutamic acid decarboxylase (GAD65) and 2C protein of coxsackievirus B4. Childhood Diabetes in Finland Study Group.
Lönnrot M; Hyöty H; Knip M; Roivainen M; Kulmala P; Leinikki P; Akerblom HK
Clin Exp Immunol; 1996 Jun; 104(3):398-405. PubMed ID: 9099922
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to glutamic acid decarboxylase and P2-C peptides in sera from coxsackie virus B4-infected mice and IDDM patients.
Hou J; Said C; Franchi D; Dockstader P; Chatterjee NK
Diabetes; 1994 Oct; 43(10):1260-6. PubMed ID: 7523207
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.
Powers AC; Bavik K; Tremble J; Daw K; Scherbaum WA; Banga JP
Clin Exp Immunol; 1999 Dec; 118(3):349-56. PubMed ID: 10594551
[TBL] [Abstract][Full Text] [Related]
7. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.
Kim J; Namchuk M; Bugawan T; Fu Q; Jaffe M; Shi Y; Aanstoot HJ; Turck CW; Erlich H; Lennon V; Baekkeskov S
J Exp Med; 1994 Aug; 180(2):595-606. PubMed ID: 7519242
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical differentiation of monoclonal GAD antibodies recognizing linear or conformational epitope regions.
Augstein P; Ziegler B; Schlosser M; Flassig S; Strebelow M; Ziegler M
Pancreas; 1997 Aug; 15(2):139-46. PubMed ID: 9260198
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes.
Ziegler B; Strebelow M; Rjasanowski I; Schlosser M; Ziegler M
Autoimmunity; 1998; 28(2):61-8. PubMed ID: 9771977
[TBL] [Abstract][Full Text] [Related]
10. Highly-sensitive and specific enzyme-linked immunosorbent assays for GAD65 autoantibodies using a thioredoxin-GAD65 fusion antigen.
Papouchado ML; Valdez SN; Ermácora MR; Gañan S; Poskus E
J Immunol Methods; 1997 Sep; 207(2):169-78. PubMed ID: 9368643
[TBL] [Abstract][Full Text] [Related]
11. Autoantigenic properties of native and denatured glutamic acid decarboxylase: evidence for a conformational epitope.
Tuomi T; Rowley MJ; Knowles WJ; Chen QY; McAnally T; Zimmet PZ; Mackay IR
Clin Immunol Immunopathol; 1994 Apr; 71(1):53-9. PubMed ID: 7511084
[TBL] [Abstract][Full Text] [Related]
12. Expression of recombinant human glutamic acid decarboxylase (GAD) in myeloma cells and enzyme-linked immunosorbent assay (ELISA) for autoantibodies to GAD.
Matsuba T; Yano M; Abiru N; Takino H; Akazawa S; Nagataki S; Yasukawa K
J Biochem; 1997 Jan; 121(1):20-4. PubMed ID: 9058186
[TBL] [Abstract][Full Text] [Related]
13. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition.
Daw K; Ujihara N; Atkinson M; Powers AC
J Immunol; 1996 Jan; 156(2):818-25. PubMed ID: 8543838
[TBL] [Abstract][Full Text] [Related]
14. Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes.
De Aizpurua HJ; Wilson YM; Harrison LC
Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9841-5. PubMed ID: 1409709
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus.
Seissler J; Amann J; Mauch L; Haubruck H; Wolfahrt S; Bieg S; Richter W; Holl R; Heinze E; Northemann W
J Clin Invest; 1993 Sep; 92(3):1394-9. PubMed ID: 8376591
[TBL] [Abstract][Full Text] [Related]
16. Brain-reactive autoantibodies in BB/d rats do not recognize glutamic acid decarboxylase.
Davenport C; Lovell H; James RF; Todd I
Clin Exp Immunol; 1995 Jul; 101(1):127-35. PubMed ID: 7621582
[TBL] [Abstract][Full Text] [Related]
17. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes.
Björk E; Velloso LA; Kämpe O; Karlsson FA
Diabetes; 1994 Jan; 43(1):161-5. PubMed ID: 7505244
[TBL] [Abstract][Full Text] [Related]
18. Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome.
Ziegler B; Schlosser M; Lühder F; Strebelow M; Augstein P; Northemann W; Powers AC; Ziegler M
Acta Diabetol; 1996 Sep; 33(3):225-31. PubMed ID: 8904930
[TBL] [Abstract][Full Text] [Related]
19. Autoantigenic reactivity of diabetes sera with a hybrid glutamic acid decarboxylase GAD67-65 molecule GAD67(1-101)/GAD65(96-585).
Teoh KL; Fida S; Rowley MJ; Mackay IR
Autoimmunity; 1998; 28(4):259-66. PubMed ID: 9892508
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in the occurrence of a subset of autoantibodies to glutamic acid decarboxylase in autoimmune polyendocrine patients with islet cell antibodies.
Davenport C; Radford PM; Al-Bukhari TA; Lai M; Bottazzo GF; Todd I
Clin Exp Immunol; 1998 Mar; 111(3):497-505. PubMed ID: 9528889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
